智通财经APP获悉，拨康视云-B(02592)盘中涨超4%，近一周交易日累计涨幅逾八成。截至发稿，涨2.71%，报8.72港元，成交额675.14万港元。
消息面上，近日，拨康视云-B发布公告，公司于美国特拉华州注册成立的全资附属公司ADS Therapeutics LLC(ADS USA)已成功在日本及欧洲成功申请专利，该等专利涉及集团核心产品之一CBT-009。
公司认为，该等专利申请的成功是CBT-009研发进程中的重要里程碑，将提升CBT-009的全球覆盖范围，并促进商业化进程。预计集团将能够与大型制药公司开展合作，就在日本及欧洲(CBT-009的关键高端市场)生产、开发及分销CBT-009建立许可安排。有关合作及许可安排预期将提升并加速CBT-009的全球商业化潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.